New drug combo aims to tame rare kidney diseases
NCT ID NCT07522099
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control the disease. Participants must have active kidney disease and meet other health criteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADX-038 (siRNA drug) and telitacicept (fusion protein)
- What this could lead to
- If successful, this could point toward a new treatment option for certain complement-mediated kidney diseases, potentially slowing disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The combination therapy also adds complexity and potential side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEMENT 3 GLOMERULOPATHY (C3G) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
ADARx Clinical Site
RECRUITINGShenzhen, Guangdong, 518100, China
-
ADARx Clinical Site
RECRUITINGGuiyang, Guizhou, China
-
ADARx Clinical Site
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
ADARx Clinical Site
RECRUITINGBaotou, Inner Mongolia, 014000, China
-
ADARx Clinical Site
RECRUITINGWuxi, Jiangsu, 214000, China
-
ADARx Clinical Site
RECRUITINGYantai, Shandong, 264008, China
-
ADARx Clinical Site
RECRUITINGBeijing, 100034, China
-
ADARx Clinical Site
RECRUITINGShandong, China
-
ADARx Clinical Site
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to stop kidney disease from coming back after transplant
- New drug shows promise for controlling rare kidney disorders
- New drug aims to slow kidney damage in IgA nephropathy
- Hope for rare kidney patients: new drug shows promise in phase 3 trial
- New drug zigakibart aims to slow kidney disease in IgA nephropathy patients
- New siRNA drug aims to tame kidney disease